. Author manuscript; available in PMC: 2020 Jul 15.

Published in final edited form as: Antib Ther. 2020 Jun 6;3(2):146–154. doi: 10.1093/abt/tbaa012

Table 2.

Anti-CD20 bispecific antibodies have a more favorable safety profile compared with CAR-Ts. CRS, cytokine release syndrome.

	Study	CRS		Neurotoxicity
	Study	All grades	Grade 3/4	All grades	Grade 3/4
bsAbs	Mosunetuzumab Group B	25.3%	Gr3: 1.1% Gr4: 0%	45.1%	2.7%
	Regeneron1979	56.8%	Gr3: 7.4% Gr4: 0%	49.5%	1.1%
	CD20-TCB ≥600 μg	55%	Gr3: 5% Gr4: 1.3%	16%	1%
CAR-T	JULIET (Tisagenlecleucel)	74%	21% Penn Scale	58%	11%
CAR-T	ZUMA-1 (Axicabtagene ciloleucel)	94%	13% Lee Criteria	87%	31%

Source: adapted from Dr. Budde’s presentation with her permission